Last reviewed · How we verify
Olmesartan medoxomil tablets
Olmesartan medoxomil blocks angiotensin II type 1 (AT1) receptors, preventing vasoconstriction and reducing blood pressure.
Olmesartan medoxomil blocks angiotensin II type 1 (AT1) receptors, preventing vasoconstriction and reducing blood pressure. Used for Hypertension, Reduction of cardiovascular risk in patients with hypertension.
At a glance
| Generic name | Olmesartan medoxomil tablets |
|---|---|
| Also known as | Benicar |
| Sponsor | Lee's Pharmaceutical Limited |
| Drug class | Angiotensin II receptor blocker (ARB) |
| Target | AT1 receptor (Angiotensin II type 1 receptor) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Olmesartan medoxomil is a prodrug that is hydrolyzed to olmesartan, an angiotensin II receptor blocker (ARB). It selectively antagonizes AT1 receptors on vascular smooth muscle and other tissues, blocking the vasoconstrictive and aldosterone-secreting effects of angiotensin II. This leads to vasodilation, reduced peripheral vascular resistance, and decreased blood pressure.
Approved indications
- Hypertension
- Reduction of cardiovascular risk in patients with hypertension
Common side effects
- Dizziness
- Hyperkalemia
- Headache
- Fatigue
- Diarrhea
Key clinical trials
- Efficacy and Safety of Olmesartan Associated With Chlorthalidone Versus Benicar HCT® in Essential Hypertension Control (PHASE3)
- Efficacy and Safety of Olmesartan Associated With Chlorthalidone in Essential Arterial Hypertension Control (PHASE3)
- Study to Evaluate the Effect of Improving Systolic BP and LDL-C Compared to Conventional Treatments and the Convenience of Taking Medication of Olostar Tab
- Reduction Efficacy of OLOMAX for Blood Pressure and Low-density Lipoprotein Cholesterol in Hypertensive Patients With Dyslipidemia
- Effect of Sacubitril/Valsartan on Cardiac Function in Hypertensive Patients Stratified by BMI: A Real World Study
- Clinical Trial to Evaluate the Efficacy and Safety of OLOMAX Tab (PHASE4)
- Fed Study of Olmesartan Medoxomil and Hydrochlorothiazide Tablets 40 mg/25 mg and Benicar HCT® Tablets 40 mg/25 mg (PHASE1)
- Fasting Study of Olmesartan Medoxomil Tablets 40 mg and Benicar® Tablets 40 mg (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Olmesartan medoxomil tablets CI brief — competitive landscape report
- Olmesartan medoxomil tablets updates RSS · CI watch RSS
- Lee's Pharmaceutical Limited portfolio CI